Stay updated with breaking news from Nasdaq Avro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aldebaran Capital LLC purchased a new position in shares of AVROBIO, Inc. (NASDAQ:AVRO – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 470,130 shares of the company’s stock, valued at approximately $724,000. AVROBIO accounts for about 0.7% of […]
AVROBIO, Inc. (NASDAQ:AVRO – Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 711,700 shares, a decrease of 22.6% from the November 30th total of 919,000 shares. Currently, 1.9% of the shares of the company are short […]
Mizuho cut shares of AVROBIO (NASDAQ:AVRO – Free Report) from a buy rating to a neutral rating in a research report released on Monday, MarketBeat Ratings reports. Mizuho currently has $2.00 target price on the stock, down from their prior target price of $5.00. AVROBIO Price Performance NASDAQ AVRO opened at $1.33 on Monday. AVROBIO […]
AVROBIO (NASDAQ:AVRO – Get Free Report) and Clarus Therapeutics (OTCMKTS:CRXTQ – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability. Institutional & Insider Ownership 60.0% of AVROBIO shares […]
AVROBIO, Inc. (NASDAQ:AVRO – Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,040,000 shares, a decline of 15.0% from the July 15th total of 2,400,000 shares. Approximately 5.5% of the company’s stock are sold short. Based on an average […]